Theralase Technologies Extends Warrant Expiry to 2027

Theralase® Technologies Inc., a clinical-stage pharmaceutical company, announced the extension of the expiry date for 1,000,000 share purchase warrants. The new expiry date is set for November 17, 2027, from the original November 17, 2024. These warrants, initially issued in November 2022 through a private placement, are exercisable at $0.35 per share. All other terms remain unchanged, pending final approval from the TSX Venture Exchange.

Theralase®, known for developing light and drug-activated small molecule compounds aimed at treating cancers, bacteria, and viruses, continues to focus on safety and efficacy. The company remains committed to advancing its research and development initiatives despite inherent risks and uncertainties related to regulatory approvals and market conditions.